NCT05574114
A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma
At risk: Primary completion moved at least 11 months later.
See at-risk trials from Memorial Sloan Kettering Cancer Center
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 12 versions: 10 with changes below, 2 re-verified with no change. See every version on ClinicalTrials.gov ↗
- Notable Primary and study completion pushed from Oct 2026 to Oct 2027
- Eligibility criteria expanded, about 14 words
- Notable Primary and study completion dates: Oct 2025 to Oct 2026v11
- Notable Eligibility criteria shortened, about 56 words
- Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 7 of 7 sites
- Notable Eligibility criteria shortened, about 53 words
- Site details revised at 1 of 7 sites
- Minor Enrollment target: 26 to 20v6
Show 4 earlier versionsHide 4 earlier versions
- Notable Eligibility criteria shortened, about 5 wordsv5
- Minor Study sites: 1 to 7v4
- Notable Eligibility criteria expanded, about 1 wordv3
- Notable Eligibility criteria expanded, about 16 wordsv2
- Study First Submitted
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Secondary (1)
Arms and interventions
For the purposes of this protocol, day 0 will be considered the date of planned CAR T infusion. BRT Part I (intervention is 9 fractions of 3 Gy to a total dose of 27 Gy). Post-BRT Phase I re- evaluation period: Following delivery of the first 9- fractions of BRT, patients will have a period for recovery, and undergo protocol-mandated reassessment (e.g., PET scan and biopsy). Patients will receive standard of care lymphodepleting chemotherapy. Substitutions to the lymphodepleting regimen will be permitted at the discretion of the treating investigator. Day -2: BRT Part II (intervention is one fraction 3 Gy to receive a total dose of 3 Gy). Day -1: No protocol scheduled treatment interventions. Day 0: Subject will receive standard of care infusion of a manufactured commercial CAR T-cell product, as an inpatient or outpatient, at the discretion of the treating investigator.
Radiation: Bridging radiotherapy (BRT)
Drugs: Conditioning chemotherapy
Biologicals: CAR T-cell product
Sites
7 sites in 1 country